THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
COSMETIC & COSMECEUTICAL INGREDIENT PROFILE CODE: [COS-10] ID: TIP-MED-000614

Kojic Acid / Kojic Acid Dipalmitate

Active Ingredient / Scientific Identity: INCI: Kojic Acid • Class: Cosmetic Science & Dermopharmaceutics • Fungal Metabolite Copper-Chelating Tyrosinase Inhibitor

⚖️ Compare 579 Drugs
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Kojic Acid / Kojic Acid Dipalmitate ([COS-10] | ID: TIP-MED-000614) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/cos-10-kojic-acid/
Generic / Entity NameKojic Acid / Kojic Acid Dipalmitate ([COS-10])
Verified Indian Brands / RefINCI Standard: Kojic Acid (IS 4707 / Cosmetics Rules, 2020 Compliant)
Pharmacological ClassCosmetic Science & Dermopharmaceutics • Fungal Metabolite Copper-Chelating Tyrosinase Inhi
Available Dosage FormsUp to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5
Regulatory ClassificationCosmetic ingredient restricted to <=1.0% under BIS IS 4707 / Cosmetics Rules, 2020.
Key Warning & Review DateSensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit re
Reviewed: 2026-11-10
Safety Matrix:⚖️ Regulatory Framework: Cosmetic ingredient restricted to <=1.0% under BIS I✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Kojic Acid / Kojic Acid Dipalmitate (TIP-MED-000614, Reference Code [COS-10]) is classified under Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Fungal Metabolite Copper-Chelating Tyrosinase Inhibitor. Within the Indian regulatory and compendial framework, it is governed under Cosmetic ingredient restricted to <=1.0% under BIS IS 4707 / Cosmetics Rules, 2020..

Verified Indian Market Examples / Compendial Status:
INCI Standard: Kojic Acid (IS 4707 / Cosmetics Rules, 2020 Compliant)
Formulation & INCI Specification: Up to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5. Regulated under the Cosmetics Rules, 2020 and Bureau of Indian Standards (BIS IS 4707).
Dosage Forms & Available Strengths:
Up to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5
Routes: Topical Epidermal / Scalp Application Only (External Cosmetic Use)

Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance

INCI Nomenclature:
Kojic Acid
Cosmetic Function:
Fungal Metabolite Copper-Chelating Tyrosinase Inhibitor
Evidence-Backed Concentration & pH Window:
Up to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5

Irritation, Sensitisation & Photoprotection Considerations: Sensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit restricts leave-on facial concentration to a maximum of 1.0%.

Chemical Stability & Formulation Incompatibilities: Free kojic acid oxidises rapidly upon exposure to air, light, and trace ferric ions (turns dark brown); Kojic Acid Dipalmitate is a more lipophilic, oxidative-stable ester derivative.

Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Cosmetic ingredient restricted to <=1.0% under BIS IS 4707 / Cosmetics Rules, 2020.

3. Mechanism of Action & Pharmacodynamics

5-hydroxy-2-(hydroxymethyl)-4-pyrone chelates the divalent copper ions (Cu2+) at the active catalytic site of tyrosinase, blocking conversion of L-tyrosine to L-DOPA and eumelanin.

4. Therapeutic Indications & Evidence-Supported Uses

  • Cosmetic tone-evening care for localized hyperpigmentation

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: Up to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5

Administration & Meal Timing: External topical use only (Up to 1.0% max in leave-on facial cosmetics; pH 4.0–5.5). Free kojic acid oxidises rapidly upon exposure to air, light, and trace ferric ions (turns dark brown); Kojic Acid Dipalmitate is a more lipophilic, oxidative-stable ester derivative.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Metabolism & Biotransformation:
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Elimination & Renal Adjustment:
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Hepatic Impairment Considerations:
Not applicable (topical external cosmetic use).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Known allergic contact dermatitis or hypersensitivity to Kojic Acid
  • Application to open wounds, abraded skin, or acute infectious dermatoses
  • Sensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit restricts leave-on facial concentration to a maximum of 1.0%.

Key Clinical Precautions: Sensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit restricts leave-on facial concentration to a maximum of 1.0%.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Sensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit restricts leave-on facial concentration to a maximum of 1.0%.
Serious / Dose-Limiting Adverse Effects:
  • Sensitisation and allergic contact dermatitis occur at concentrations >1% or with oxidised products; SCCS/BIS safety limit restricts leave-on facial concentration to a maximum of 1.0%.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Free kojic acid oxidises rapidly upon exposure to air, light, and trace ferric ions (turns dark brown); Kojic Acid Dipalmitate is a more lipophilic, oxidative-stable ester derivative.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Free kojic acid oxidises rapidly upon exposure to air, light, and trace ferric ions (turns dark brown); Kojic Acid Dipalmitate is a more lipophilic, oxidative-stable ester derivative.

Pharmacist Patient Counselling Points:

  • Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
  • Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
  • Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.

Storage, Stability & Dispensing Safeguards: Free kojic acid oxidises rapidly upon exposure to air, light, and trace ferric ions (turns dark brown); Kojic Acid Dipalmitate is a more lipophilic, oxidative-stable ester derivative.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.

Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/cos-10-kojic-acid/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.